Mechanism of Eccentric Cardiomyocyte Hypertrophy Secondary to Mitral Regurgitation

二尖瓣反流继发偏心心肌细胞肥大的机制

基本信息

  • 批准号:
    10565204
  • 负责人:
  • 金额:
    $ 59.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-01 至 2027-04-30
  • 项目状态:
    未结题

项目摘要

Valvular heart disease represents a major public health problem worldwide. The incidence of valvular heart disease increases with age, and it is estimated that about 15% of the population above the age of 75 years suffer from some form of significant valvular disorder. Mitral regurgitation (MR) is the most frequent form of valvular heart diseases, where it is estimated that moderate and severe MR occurs at a frequency of 1.7% as adjusted to the US adult population, and up to 5% of the population in Europe have significant mitral valve disease. The natural history of chronic MR is characterized by a compensated hemodynamic state in its early phases, followed by a gradual progressive left ventricular (LV) remodeling and eccentric hypertrophy resulting in heart failure. MR patients with depressed systolic function can present a difficult management dilemma; corrective valve surgery is not recommended, and medical therapy is ineffective in preventing LV dysfunction. It should perhaps be not surprising that medical therapy for MR has repeatedly failed, since very little is known about the molecular mechanisms of myocardial dysfunction associated with primary severe MR, perhaps owing to the paucity of research tools. One of the major limitations in understanding the molecular mechanisms of myocardial response to severe MR lies in the lack of mouse models. Although several elegant large animal studies, and even a rat MR model have been published, the mechanism of eccentric hypertrophy and myocardial dysfunction secondary to severe MR is not known. Therefore, the overall goal of this project is to understand the mechanistic basis of LV systolic dysfunction secondary to severe MR that can guide the development of new therapeutic strategies. In the current proposal, we developed the first mouse model of MR. Valvular damage was achieved by severing the MV leaflets and chords using iridectomy scissors, and severe MR was confirmed by echocardiography. We found that this model recapitulates the effect of severe MR on the human myocardium with eccentric hypertrophy, systolic dysfunction, and activation of canonical hypertrophy pathways. In addition, we found evidence of activation of directional cell growth as a possible mechanism of longitudinal cardiomyocyte growth in response to MR. Therefore, we hypothesize that MR-induced eccentric cardiomyocyte hypertrophy is mediated by activation of canonical hypertrophy pathways in conjunction with directional cell growth. There are three aims: Determine the role of oxidative DNA damage in regulating eccentric cardiomyocyte hypertrophy in response to severe MR. To determine the role of Crb2 in regulation of cardiomyocyte shape during postnatal development and in response to hypertrophic stimuli. Finally, we aim to identify the spatial pattern of sarcomeric mRNA translation during cardiomyocyte hypertrophy in response to MR.
心脏瓣膜病是世界范围内的一个重大公共卫生问题。心脏瓣膜病的发生率 疾病随着年龄的增长而增加,据估计,75岁以上的人口中约有15% 患有某种形式的严重心脏瓣膜紊乱。二尖瓣返流(MR)是最常见的 心脏瓣膜病,据估计,中度和重度MR发生的频率为1.7% 适应美国成年人口,欧洲高达5%的人口有明显的二尖瓣 疾病。慢性MR的自然病程以早期代偿血流动力学状态为特征。 各阶段,随后逐渐进行的左心室(LV)重构和离心性肥厚导致 在心力衰竭方面。收缩功能受抑的MR患者可能会出现困难的管理困境; 不推荐进行瓣膜矫正术,药物治疗对预防左心功能不全无效。 MR的药物治疗一再失败也许并不令人惊讶,因为人们对此知之甚少。 关于与原发性重症MR相关的心肌功能障碍的分子机制,也许 由于研究工具的缺乏。 了解心肌对严重MR反应的分子机制的主要限制之一 在于缺乏老鼠模型。尽管几项优雅的大型动物研究,甚至是大鼠MR模型 已有文献报道,继发性离心性肥厚和心肌功能不全的机制 严重的MR尚不清楚。因此,本课题的总体目标是了解LV的力学基础。 继发于重度MR的收缩功能障碍,可以指导新的治疗策略的发展。在……里面 目前的建议是,我们研制出第一只小鼠的瓣膜损伤模型是通过切断 经超声心动图证实,用虹膜切除剪刀剪出MV小叶和弦线,并显示重度MR。我们 结果发现,该模型重现了严重MR对偏心性心肌的影响 肥厚、收缩功能障碍和典型肥厚通路的激活。另外,我们发现, 定向细胞生长激活作为心肌细胞纵向生长的可能机制的证据 因此,为了回应MR先生,我们假设MR诱导的离心性心肌细胞肥大是 通过激活规范的肥大通路与定向细胞生长相结合。确实有 三个目标:确定氧化DNA损伤在调节心肌细胞离心性肥大中的作用 对重度MR的反应以确定Crb2在出生后心肌细胞形状调节中的作用 发展和对肥大刺激的反应。最后,我们的目标是确定 心肌细胞肥大过程中肌瘤基因的翻译

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stavros George Drakos其他文献

COST EFFECTIVENESS ANALYSIS OF ECMO WITH ADJUNCT VENTRICULAR UNLOADING DEVICE COMPARED TO ECMO
  • DOI:
    10.1016/s0735-1097(24)04530-3
  • 发表时间:
    2024-04-02
  • 期刊:
  • 影响因子:
  • 作者:
    Kaan Raif;Stavros George Drakos;Craig H. Selzman;Joshua Horns;Joseph Tonna
  • 通讯作者:
    Joseph Tonna
SPHINGOLIPIDS AS POTENTIAL SURROGATES OF MYOCARDIAL RECOVERY IN LEFT VENTRICULAR ASSIST DEVICE PATIENTS
  • DOI:
    10.1016/s0735-1097(23)00741-6
  • 发表时间:
    2023-03-07
  • 期刊:
  • 影响因子:
  • 作者:
    Rana Hamouche;Sean Tatum;Elizabeth Dranow;Christos P. Kyriakopoulos;Thirupura Sundari Shankar;Joseph Visker;Jing Ling;Konstantinos Sideris;Craig H. Selzman;Abdallah G. Kfoury;Josef Stehlik;Rami Alharethi;James C. Fang;Sutip Navankasattusas;William Holland;Scott Summers;Stavros George Drakos;Eleni Tseliou
  • 通讯作者:
    Eleni Tseliou
IMPAIRED LIVER FUNCTION IS ASSOCIATED WITH HYPOTENSION AND ELEVATED RIGHT ATRIAL PRESSURE BUT NOT DEPRESSED CARDIAC INDEX IN CHRONIC HEART FAILURE
  • DOI:
    10.1016/s0735-1097(23)00919-1
  • 发表时间:
    2023-03-07
  • 期刊:
  • 影响因子:
  • 作者:
    Christos Kapelios;Eleni Tseliou;Rami Alharethi;Kevin Shah;Thomas Hanff;Christos P. Kyriakopoulos;Konstantinos Sideris;Iosif Taleb;Josef Stehlik;Spencer Carter;Abdallah G. Kfoury;William Caine;Craig H. Selzman;James C. Fang;Omar Wever-Pinzon;Stavros George Drakos
  • 通讯作者:
    Stavros George Drakos
Functional and Structural Myocardial Improvement after LVAD Therapy: The U-NOVA Reverse Remodeling Stages
  • DOI:
    10.1016/j.cardfail.2019.07.190
  • 发表时间:
    2019-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Shah Palak;Mitchell Psotka;Iosif Taleb;Rami Alharethi;Mortada A. Shams;Omar Wever-Pinzon;Michael Yin;Federica Latta;Josef Stehlik;James C. Fang;Ramesh Singh;Craig H. Selzman;Abdallah Kfoury;Stavros George Drakos
  • 通讯作者:
    Stavros George Drakos
HEALTH RELATED QUALITY OF LIFE AS PREDICTOR OF OUTCOMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
  • DOI:
    10.1016/s0735-1097(23)01057-4
  • 发表时间:
    2023-03-07
  • 期刊:
  • 影响因子:
  • 作者:
    Konstantinos Sideris;Mingyuan Zhang;Alfonso F. Siu;Peter Wohlfahrt;Jincheng Shen;Christos P. Kyriakopoulos;Iosif Taleb;Omar Wever-Pinzon;Kevin Shah;Craig H. Selzman;Carlos Rodriguez Correa;Christos Kapelios;Lina M. Brinker;Rami Alharethi;Rachel Hess;Stavros George Drakos;Benjamin Adam Steinberg;Abdallah G. Kfoury;John A. Spertus;James C. Fang
  • 通讯作者:
    James C. Fang

Stavros George Drakos的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stavros George Drakos', 18)}}的其他基金

Perm1 is a Novel Regulator of Cardiac Energetics and Function
Perm1 是一种新型的心脏能量和功能调节剂
  • 批准号:
    10547828
  • 财政年份:
    2020
  • 资助金额:
    $ 59.4万
  • 项目类别:
Perm1 is a Novel Regulator of Cardiac Energetics and Function
Perm1 是一种新型的心脏能量和功能调节剂
  • 批准号:
    10631449
  • 财政年份:
    2020
  • 资助金额:
    $ 59.4万
  • 项目类别:
Perm1 is a Novel Regulator of Cardiac Energetics and Function
Perm1 是一种新型的心脏能量和功能调节剂
  • 批准号:
    10730363
  • 财政年份:
    2020
  • 资助金额:
    $ 59.4万
  • 项目类别:
Perm1 is a Novel Regulator of Cardiac Energetics and Function
Perm1 是一种新型的心脏能量和功能调节剂
  • 批准号:
    10523981
  • 财政年份:
    2020
  • 资助金额:
    $ 59.4万
  • 项目类别:
Understanding Myocardial Recovery in Diabetes and Heart Failure
了解糖尿病和心力衰竭的心肌恢复
  • 批准号:
    10426081
  • 财政年份:
    2020
  • 资助金额:
    $ 59.4万
  • 项目类别:
Perm1 is a Novel Regulator of Cardiac Energetics and Function
Perm1 是一种新型的心脏能量和功能调节剂
  • 批准号:
    10156104
  • 财政年份:
    2020
  • 资助金额:
    $ 59.4万
  • 项目类别:
Understanding Myocardial Recovery in Diabetes and Heart Failure
了解糖尿病和心力衰竭的心肌恢复
  • 批准号:
    10595643
  • 财政年份:
    2020
  • 资助金额:
    $ 59.4万
  • 项目类别:
Clinical and Metabolic Signature of Recovered Myocardium in Human Heart Failure
人类心力衰竭恢复心肌的临床和代谢特征
  • 批准号:
    9218590
  • 财政年份:
    2016
  • 资助金额:
    $ 59.4万
  • 项目类别:
Clinical and Metabolic Signature of Recovered Myocardium in Human Heart Failure
人类心力衰竭恢复心肌的临床和代谢特征
  • 批准号:
    10066362
  • 财政年份:
    2016
  • 资助金额:
    $ 59.4万
  • 项目类别:
Training in Cardiovascular Research
心血管研究培训
  • 批准号:
    10626716
  • 财政年份:
    1994
  • 资助金额:
    $ 59.4万
  • 项目类别:

相似海外基金

Developing a Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening among Rural Screening Age-Eligible Adults
制定年轻人介导的干预措施,以增加农村符合筛查年龄的成年人的结直肠癌筛查
  • 批准号:
    10653464
  • 财政年份:
    2023
  • 资助金额:
    $ 59.4万
  • 项目类别:
Doctoral Dissertation Research: Estimating adult age-at-death from the pelvis
博士论文研究:从骨盆估算成人死亡年龄
  • 批准号:
    2316108
  • 财政年份:
    2023
  • 资助金额:
    $ 59.4万
  • 项目类别:
    Standard Grant
Determining age dependent factors driving COVID-19 disease severity using experimental human paediatric and adult models of SARS-CoV-2 infection
使用 SARS-CoV-2 感染的实验性人类儿童和成人模型确定导致 COVID-19 疾病严重程度的年龄依赖因素
  • 批准号:
    BB/V006738/1
  • 财政年份:
    2020
  • 资助金额:
    $ 59.4万
  • 项目类别:
    Research Grant
Transplantation of Adult, Tissue-Specific RPE Stem Cells for Non-exudative Age-related macular degeneration (AMD)
成人组织特异性 RPE 干细胞移植治疗非渗出性年龄相关性黄斑变性 (AMD)
  • 批准号:
    10294664
  • 财政年份:
    2020
  • 资助金额:
    $ 59.4万
  • 项目类别:
Sex differences in the effect of age on episodic memory-related brain function across the adult lifespan
年龄对成人一生中情景记忆相关脑功能影响的性别差异
  • 批准号:
    422882
  • 财政年份:
    2019
  • 资助金额:
    $ 59.4万
  • 项目类别:
    Operating Grants
Modelling Age- and Sex-related Changes in Gait Coordination Strategies in a Healthy Adult Population Using Principal Component Analysis
使用主成分分析对健康成年人群步态协调策略中与年龄和性别相关的变化进行建模
  • 批准号:
    430871
  • 财政年份:
    2019
  • 资助金额:
    $ 59.4万
  • 项目类别:
    Studentship Programs
Transplantation of Adult, Tissue-Specific RPE Stem Cells as Therapy for Non-exudative Age-Related Macular Degeneration AMD
成人组织特异性 RPE 干细胞移植治疗非渗出性年龄相关性黄斑变性 AMD
  • 批准号:
    9811094
  • 财政年份:
    2019
  • 资助金额:
    $ 59.4万
  • 项目类别:
Study of pathogenic mechanism of age-dependent chromosome translocation in adult acute lymphoblastic leukemia
成人急性淋巴细胞白血病年龄依赖性染色体易位发病机制研究
  • 批准号:
    18K16103
  • 财政年份:
    2018
  • 资助金额:
    $ 59.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Doctoral Dissertation Research: Literacy Effects on Language Acquisition and Sentence Processing in Adult L1 and School-Age Heritage Speakers of Spanish
博士论文研究:识字对西班牙语成人母语和学龄传统使用者语言习得和句子处理的影响
  • 批准号:
    1823881
  • 财政年份:
    2018
  • 资助金额:
    $ 59.4万
  • 项目类别:
    Standard Grant
Adult Age-differences in Auditory Selective Attention: The Interplay of Norepinephrine and Rhythmic Neural Activity
成人听觉选择性注意的年龄差异:去甲肾上腺素与节律神经活动的相互作用
  • 批准号:
    369385245
  • 财政年份:
    2017
  • 资助金额:
    $ 59.4万
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了